Key Takeaways
- Novo Nordisk (NVO) shares plunged 12% after its EVOKE Phase 3 trials for semaglutide in Alzheimer's disease failed to demonstrate a statistically significant reduction in disease progression.
- European leaders, including German Chancellor Merz, Polish Prime Minister Tusk, and EU Commission President von der Leyen, signaled renewed momentum in Ukraine peace talks, emphasizing the need for a strong Ukrainian army and solid security guarantees.
- Polish PM Tusk indicated that the European Union is nearing a decision on utilizing frozen Russian assets to fund Ukraine's reconstruction efforts.
- US Commerce Secretary Lutnick detailed ongoing US-EU trade discussions, noting the EU's interest in changes to steel regulations and the US's focus on digital rules and big tech.
- A proposed generational smoking ban in Northern Ireland is reportedly facing EU pushback from member states like Greece, Slovakia, and Romania, citing potential breaches of single market principles.
European leaders convened today, expressing a unified stance on Ukraine's future and progress in peace negotiations, while a major pharmaceutical company faced a significant setback in its Alzheimer's research. Meanwhile, US and EU officials continued discussions on critical trade matters, and a proposed smoking ban sparked controversy.
Ukraine's Path Forward: Peace Talks and Frozen Assets
There is "new momentum" on Ukraine peace talks, with "significant progress" reported, according to EU's Costa. German Chancellor Merz reiterated that Ukraine requires a strong army and solid security guarantees, asserting that Ukraine cannot be compelled to surrender territory. Merz also stressed that any peace plan for Ukraine must have European backing and that peace cannot be achieved overnight.
EU Commission President Ursula von der Leyen reaffirmed that Ukraine's territory and sovereignty must be respected, and that only Ukraine can make decisions regarding its forces and destiny. Polish Prime Minister Donald Tusk indicated that the EU is "closer to a decision" that would allow frozen Russian funds to be used for Ukraine's reconstruction. This development marks a potential breakthrough in funding the war-torn nation's rebuilding efforts.
Novo Nordisk's Alzheimer's Setback
Pharmaceutical giant Novo Nordisk (NVO) saw its shares fall by 12% after announcing disappointing results from its EVOKE Phase 3 trials for semaglutide in Alzheimer's disease. The trials did not confirm the superiority of semaglutide over placebo in reducing the progression of Alzheimer's disease, nor did they demonstrate a statistically significant reduction in disease progression.
While semaglutide improved biomarkers, it did not delay disease progression. Consequently, the one-year extension period in the EVOKE and EVOKE+ trials will be discontinued based on the observed efficacy results. The full results are slated for presentation at the CTAD conference on December 3, 2025.
US-EU Trade Discussions and Chip Security
US Commerce Secretary Lutnick provided insights into ongoing trade negotiations between the US and the EU. Lutnick noted that the EU is seeking changes in the area of steel regulations, while the US is focused on digital rules. These discussions also encompass rules on Big Tech.
Lutnick expressed confidence that "best" US chips would not fall into the "wrong hands" and suggested that a recent chips deal with Saudi Arabia could serve as a model for other agreements. He also mentioned that talks with China would "work their way through" and that the US is actively seeking to enhance the US-EU deal.
EU Pushback on Northern Ireland Smoking Ban
In a separate development, Starmer's proposed generational smoking ban in Northern Ireland is reportedly facing pushback from several EU member states. Greece, Slovakia, and Romania are among the countries suggesting that the ban breaches Single Market principles. This indicates potential friction between the UK's internal policies and broader EU trade regulations.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.